Dasolampanel Explained

Dasolampanel (INN, USAN, code name NGX-426) is an orally bioavailable analog of tezampanel and thereby competitive antagonist of the AMPA and kainate receptors which was under development by Raptor Pharmaceuticals/Torrey Pines Therapeutics for the treatment of chronic pain conditions including neuropathic pain and migraine.[1] It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection,[2] [3] but ultimately neither drug was ever marketed.

See also

Notes and References

  1. Book: Stolerman IP . Encyclopedia of Psychopharmacology. 31 July 2010. Springer Science & Business Media. 978-3-540-68698-9. 514–.
  2. Book: Olesen J, Ramadan N . Innovative Drug Development for Headache Disorders. 21 August 2008. Oxford University Press. 978-0-19-955276-4. 188–.
  3. Book: Firestein GS, Budd R, Gabriel SE, O'Dell JR, McInnes IB . Kelley's Textbook of Rheumatology: Expert Consult Premium Edition: Enhanced Online Features. 31 August 2012. Elsevier Health Sciences. 978-1-4557-3767-3. 1031–.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Dasolampanel".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.